Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
ILUVIEN continues to show positive results in Europe

ILUVIEN continues to show positive results in Europe

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences announces results from ongoing study on ILUVIEN

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

Trained nurses administer AMD treatments as safely and effectively as doctors

Trained nurses administer AMD treatments as safely and effectively as doctors

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Retinal function affected early in Type 1, 2 diabetes

Retinal function affected early in Type 1, 2 diabetes

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

LSDF announces $1.2 million in grants to foster advancement of promising health-related technologies

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics announces corporate update and Q3 2014 financial results

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV